C4 Therapeutics, Inc. Profile Avatar - Palmy Investing

C4 Therapeutics, Inc.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7…

Biotechnology
US, Watertown [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

C4 Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of CCCC's Analysis
CIK: 1662579 CUSIP: 12529R107 ISIN: US12529R1077 LEI: - UEI: -
Secondary Listings
CCCC has no secondary listings inside our databases.